# India Non Alcoholic Steatohepatitis Biomarkers Market > India Non-Alcoholic Steatohepatitis Biomarkers Market Research Report By Type (Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Others) and By End User (Research Institutes and Academics, Diagnostic Centres, Pharmaceutical Companies and CROs, Hospitals and Clinics, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 26.19% - **2024:** $ 6 Million - **2025:** $ 7.57 Million - **2035:** $ 77.54 Million - **Key Players:** Gilead Sciences (US), Intercept Pharmaceuticals (US), Bristol-Myers Squibb (US), Echosens (FR), Celerion (US), Genfit (FR), Pfizer (US), Novartis (CH), Hepion Pharmaceuticals (US) **Report ID:** MRFR/HC/47965-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-non-alcoholic-steatohepatitis-biomarkers-market-49719 --- ## Market Summary ## **India Non-Alcoholic Steatohepatitis Biomarkers Market Overview** As per MRFR analysis, the India Non-Alcoholic Steatohepatitis Biomarkers Market Size was estimated at 6 (USD Million) in 2023. The India Non-Alcoholic Steatohepatitis Biomarkers Market Industry is expected to grow from 10.5(USD Million) in 2024 to 150.3 (USD Million) by 2035. The India Non-Alcoholic Steatohepatitis Biomarkers Market CAGR (growth rate) is expected to be around 27.371% during the forecast period (2025 - 2035) **Key India Non-Alcoholic Steatohepatitis Biomarkers Market Trends Highlighted** The India Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market is being driven by an increasing prevalence of obesity and metabolic syndrome in the region. The Indian government's initiatives for health awareness, such as the National Health Mission, have emphasized the importance of preventive healthcare, which extends to the early diagnosis of conditions like NASH. As lifestyle diseases become more common, the demand for effective biomarkers to diagnose and monitor liver health is rising.  Additionally, advancements in medical technology and increased investment in healthcare infrastructure provide opportunities for the development of innovative diagnostic tools and treatments for NASH.Recent trends indicate a growing interest from pharmaceutical companies in research and development focused on NASH biomarkers. This interest is bolstered by the increasing recognition of NASH as a significant public health issue in India, with better diagnostics potentially leading to improved treatment pathways. Expanding collaborations between research institutions and the biotech industry are also notable trends.  This collaboration aims to validate new biomarkers and create targeted therapies, driving market growth. Opportunities exist for health professionals and organizations to enhance education and awareness around NASH, thus fostering a proactive approach to liver health among the Indian population.Furthermore, as the population ages and urbanization increases, there is a potential to expand the market for NASH biomarkers through greater access to healthcare services. Overall, the India Non-Alcoholic Steatohepatitis Biomarkers Market is evolving, with various dynamics and trends shaping its future landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **India Non-Alcoholic Steatohepatitis Biomarkers Market Drivers** **Rising Prevalence of Obesity in India** One of the main causes of the increase in Non-Alcoholic Steatohepatitis (NASH) patients is obesity. Approximately 135 million persons in India were categorized as overweight or obese in 2019, according to the Global Burden of Disease research, which shows that the incidence of obesity has quadrupled over the previous 20 years. There is a significant need for non-alcoholic steatohepatitis biomarkers in the India non-alcoholic steatohepatitis biomarkers market industry due to the rising trend in obesity, which is directly correlated with increased incidences of NASH. New diagnostic techniques in the NASH biomarker arena will probably be encouraged, and more research and development investments will be made as long as healthcare organizations like the Indian Council of Medical Research (ICMR) continue to draw attention to the burden of metabolic illnesses. **Growing Awareness and Screening for Liver Diseases** The increasing awareness regarding liver diseases, including NASH, is another key driver for the India Non-Alcoholic Steatohepatitis Biomarkers Market Industry. Recent initiatives by the Ministry of Health and Family Welfare in India, which underscore the importance of screening for liver health, are encouraging regular health check-ups. This regulatory focus on early detection is anticipated to boost the demand for reliable biomarkers to monitor liver health effectively.Furthermore, public campaigns led by organizations like the Hepatitis Foundation of India have ramped up screening efforts, resulting in an uptick of approximately 30% in liver-related health check-ups since 2021. **Increase in Healthcare Spending** There has been a significant increase in healthcare spending in India, which supports the growth of the Non-Alcoholic Steatohepatitis biomarkers segment. As per the National Health Mission reports, India has pledged to increase its healthcare expenditure to 2.5% of the Gross Domestic Product (GDP) by 2025. This funding is likely to lead to the development and implementation of advanced diagnostic technologies for NASH. With important entities such as the World Health Organization advocating for improved health infrastructure, the infusion of funds can catalyze growth in the India Non-Alcoholic Steatohepatitis Biomarkers Market, enabling more organizations to research and commercialize their biomarkers. **India Non-Alcoholic Steatohepatitis Biomarkers Market Segment Insights** **Non-Alcoholic Steatohepatitis Biomarkers Market Type Insights** The India Non-Alcoholic Steatohepatitis Biomarkers Market is witnessing considerable advancement due to the rising incidences of liver diseases and the increasing awareness regarding non-alcoholic fatty liver disease among the population. The market is segmented Type wise into various categories, each contributing significantly to the overall landscape of the industry. Hepatic Fibrosis Biomarkers play a critical role in assessing the degree of fibrosis in patients, allowing healthcare professionals to evaluate the progression of liver damage more accurately.This segment has gained prominence due to its ability to predict adverse liver-related outcomes, making it essential for timely intervention and management.  Similarly, Serum Biomarkers are significant in this market as they offer a non-invasive means to monitor liver health and assess the presence and severity of non-alcoholic steatohepatitis. The convenience and efficiency of serum testing make it a preferred choice among clinicians, thus elevating its impact on diagnostics. Oxidative Stress Biomarkers underscore the importance of cellular damage assessment in the context of non-alcoholic steatohepatitis, as they are directly linked with the pathophysiological mechanisms of the disease.In India, rising oxidative stress levels due to lifestyle factors have made this segment pivotal in contemporary research.  Apoptosis Biomarkers are also noteworthy, as they relate to programmed cell death mechanisms, which have significant implications in liver diseases. Understanding apoptosis can help in determining the efficacy of treatments and assessing disease progression. Finally, the 'Others' category encompasses a range of emerging biomarkers that cater to specific research needs and diagnostic requirements, addressing niche areas that could provide extensive insights into non-alcoholic steatohepatitis.These diverse Types within the market collectively drive innovation, research, and improved patient outcomes in the context of liver health management, resonating with the expanding healthcare framework in India.  The overall growth dynamics of the India Non-Alcoholic Steatohepatitis Biomarkers Market reflect a burgeoning demand for effective diagnostics and interventions, thus highlighting the critical nature of market segmentation in shaping future healthcare strategies. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Non-Alcoholic Steatohepatitis Biomarkers Market End User Insights** The India Non-Alcoholic Steatohepatitis Biomarkers Market is significantly influenced by its End User segment, which comprises various entities that play crucial roles in the assessment and treatment of this condition. Research Institutes and Academics are pivotal in advancing understanding and driving innovations in biomarkers, thus contributing to their development and validation. Diagnostic Centres are essential as they facilitate early detection and monitoring, allowing for timely therapeutic interventions. Pharmaceutical Companies and Contract Research Organizations (CROs) are key players engaging in the development of novel medications and conducting clinical trials, which are necessary for bringing effective solutions to market. Hospitals and Clinics serve a critical function, offering comprehensive care and treatment services, making them a vital point of contact for patients diagnosed with the condition. Other entities, which may include regulatory and health policy organizations, are also crucial as they shape market frameworks critical for the deployment of biomarkers in healthcare settings. This diversity within the End User segment highlights the collaborative effort needed to tackle Non-Alcoholic Steatohepatitis in India and underscores the growing importance of biomarkers in patient management and treatment outcomes.Collectively, these insights highlight the growth potential in the India Non-Alcoholic Steatohepatitis Biomarkers Market driven by increasing prevalence and awareness associated with this disease. **India Non-Alcoholic Steatohepatitis Biomarkers Market Key Players and Competitive Insights** The India Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market has been experiencing significant growth, driven by the increasing prevalence of obesity, diabetes, and metabolic syndrome, which heighten the demand for effective diagnostic solutions. In this rapidly evolving landscape, several key players are vying for market share by developing innovative biomarkers that enhance the detection, diagnosis, and characterization of NASH. The competitive dynamics of this market reveal a robust interplay between established pharmaceutical companies, emerging biotech firms, and diagnostic laboratories, contributing to advancements in research and technology.  As awareness of NASH rises among healthcare professionals and patients alike, the competition among stakeholders is expected to intensify, leading to a more diverse portfolio of products and services designed to meet the growing demands of this segment within India.Merck and Co has solidified its presence in the India Non-Alcoholic Steatohepatitis Biomarkers Market through its commitment to research and development, focusing on the exploration of biomarkers for liver diseases, including NASH. The company possesses strong capabilities in innovative drug development, which enhance its ability to produce effective biomarkers and diagnostic tools tailored for the Indian population.  Its established relationships with healthcare professionals and institutions in India further bolster its market position. Additionally, Merck and Co's comprehensive understanding of metabolic diseases allows it to integrate significant scientific expertise into the development of its product offerings, thereby catering to the unique needs of Indian patients and contributing to enhanced diagnostic accuracy in clinical practice.LabCorp has emerged as a notable player in the India Non-Alcoholic Steatohepatitis Biomarkers Market, offering a robust suite of diagnostic services and biomarker testing solutions.  The company has established itself through its extensive laboratory network across India, allowing for efficient sample processing and results delivery. LabCorp's strengths lie in its advanced analytical techniques and the development of specific assays for the detection of NASH, which aid clinicians in identifying and managing liver diseases effectively. Moreover, LabCorp's strategic partnerships and collaborations with local healthcare providers enhance its reach and service capabilities within the Indian market.  The company continues to invest in innovation and expand its offerings through mergers and acquisitions, positioning itself favorably to meet the rising demand for NASH biomarkers in India. By focusing on localized needs and continuously adapting to the evolving market landscape, LabCorp maintains a competitive edge in providing essential diagnostic services for the management of NASH. **Key Companies in the India Non-Alcoholic Steatohepatitis Biomarkers Market Include** **India Non-Alcoholic Steatohepatitis Biomarkers Market Industry Developments** Recent developments in the India Non-Alcoholic Steatohepatitis Biomarkers Market indicate significant growth and interest from major companies such as Merck and Co, LabCorp, and Gilead Sciences. The market is seeing advancements in Research and Development efforts aimed at enhancing diagnostic capabilities for Non-Alcoholic Steatohepatitis (NASH). In August 2023, Merck and Co. announced strategic collaborations to accelerate biomarker discovery in liver diseases, which is expected to bolster their market position significantly. In addition, LabCorp's introduction of innovative testing solutions for NASH biomarkers has sparked interest among healthcare providers, addressing the rising prevalence of metabolic disorders in India.  The Indian government has emphasized the importance of early detection and management of liver diseases, further driving the market's growth. There have been no notable mergers or acquisitions among the specified companies in recent months. However, the ongoing focus on biomarker research is likely to lead to increased investments and partnerships, which will transform the landscape of the NASH biomarkers market in India. With rising health consciousness, the demand for effective testing solutions continues to surge, reflecting positively on the market dynamics and growth potential of key players. **India Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation Insights** ## Market Drivers ### Rising Obesity Rates The escalating rates of obesity in India are significantly impacting the non alcoholic-steatohepatitis-biomarkers market. With obesity being a major risk factor for NAFLD and NASH, the increasing prevalence of overweight individuals is likely to drive demand for effective biomarkers. According to recent health surveys, nearly 30% of the adult population in urban areas is classified as obese. This alarming trend suggests a growing need for diagnostic tools that can help in the early detection of liver-related issues. Consequently, the market for biomarkers is expected to expand as healthcare providers seek reliable methods to assess liver health in this demographic. ### Increasing Awareness of Liver Health The growing awareness regarding liver health in India is a crucial driver for the non alcoholic-steatohepatitis-biomarkers market. Public health campaigns and educational initiatives have highlighted the risks associated with liver diseases, including non alcoholic fatty liver disease (NAFLD). As a result, healthcare professionals and patients are increasingly seeking diagnostic solutions to identify liver conditions early. This heightened awareness is likely to lead to a surge in demand for biomarkers that can accurately diagnose and monitor non alcoholic steatohepatitis (NASH). The market is projected to grow as more individuals recognize the importance of liver health, potentially increasing the market size by approximately 15% over the next few years. ### Advancements in Diagnostic Technologies Technological innovations in diagnostic tools are propelling the non alcoholic-steatohepatitis-biomarkers market forward. The introduction of advanced imaging techniques and molecular diagnostics has enhanced the ability to detect and monitor liver diseases. These advancements allow for more precise identification of biomarkers associated with NASH, thereby improving patient outcomes. In India, the integration of artificial intelligence and machine learning in diagnostic processes is gaining traction, potentially streamlining the identification of liver conditions. As these technologies become more accessible, the market is likely to experience substantial growth, with an estimated increase of 20% in the adoption of biomarker tests over the next five years. ### Growing Demand for Personalized Medicine The shift towards personalized medicine in India is emerging as a significant driver for the non alcoholic-steatohepatitis-biomarkers market. Patients and healthcare providers are increasingly seeking tailored treatment options based on individual health profiles. Biomarkers play a pivotal role in this approach, enabling clinicians to make informed decisions regarding diagnosis and treatment plans for NASH. The demand for personalized healthcare solutions is likely to stimulate the market, as more patients are evaluated using specific biomarkers that reflect their unique conditions. This trend could lead to a market expansion of around 18% as personalized medicine becomes more prevalent in clinical practice. ### Government Initiatives for Health Improvement Government initiatives aimed at improving public health are influencing the non alcoholic-steatohepatitis-biomarkers market. Programs focused on lifestyle modifications, nutrition, and disease prevention are being implemented to combat the rising incidence of liver diseases. The Indian government has recognized the need for early detection and management of liver conditions, leading to increased funding for research and development in biomarker discovery. This support is expected to foster innovation in the market, encouraging the development of new diagnostic tools. As a result, the market may see a growth rate of approximately 12% as these initiatives take effect. ## Future Outlook The [Non Alcoholic Steatohepatitis Biomarkers Market](https://www.marketresearchfuture.com/reports/non-alcoholic-steatohepatitis-biomarkers-market-7984) is projected to grow at a 26.19% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in diagnostic technologies. **New opportunities:** - Development of point-of-care testing devices for rapid diagnosis - Investment in AI-driven data analytics for personalized treatment plans - Partnerships with healthcare providers for integrated biomarker solutions By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Type: Hepatic Fibrosis Biomarkers (Largest) vs. Serum Biomarkers (Fastest-Growing) In the India non alcoholic-steatohepatitis-biomarkers market, Hepatic Fibrosis Biomarkers lead the segment share, reflecting their established importance in diagnosing liver diseases. This segment captures a significant portion of the market, underscoring the dependence on these biomarkers for understanding patient conditions. Conversely, Serum Biomarkers are gaining traction and are projected to grow at a rapid pace, driven by advancements in diagnostic technologies and increasing awareness around liver health among healthcare providers and patients alike. The growth of the India non alcoholic-steatohepatitis-biomarkers market is primarily fueled by increasing incidences of non-alcoholic fatty liver disease and rising healthcare expenditures. The awareness and focus on early diagnosis in chronic liver diseases further catalyze the demand for effective biomarkers. Technological advancements in biomarker discovery and analytical approaches are also propelling this segment forward, creating a compelling landscape for both established and emerging biomarkers. Hepatic Fibrosis Biomarkers (Dominant) vs. Serum Biomarkers (Emerging) Hepatic Fibrosis Biomarkers serve as the dominant force in the India non alcoholic-steatohepatitis-biomarkers market, primarily due to their critical role in diagnosing and staging liver fibrosis. They provide crucial insights into the progression of liver disease, making them indispensable for clinicians. On the other hand, Serum Biomarkers represent an emerging category that is rapidly evolving. These biomarkers offer the advantage of non-invasive testing, a factor that significantly enhances patient compliance and accessibility. As more serum-based tests receive validation and approval, their market presence is expected to increase, providing valuable alternatives to traditional methods and highlighting the growing need for innovative diagnostic solutions. ### By End User: Hospitals and Clinics (Largest) vs. Pharmaceutical Companies and CROs (Fastest-Growing) The market share distribution among the segment values in the India non alcoholic-steatohepatitis-biomarkers market highlights that Hospitals and Clinics hold the largest portion due to their extensive patient base and direct engagement with patients for diagnosis and treatment. Diagnostic Centres also contribute significantly to this landscape, though their share is smaller compared to Hospitals. Research Institutes and Academics, while important for innovation, represent a niche segment of the market. Others encompass various smaller entities contributing limited share yet playing a role in overall market dynamics. Growth trends in this market segment show a remarkable trajectory, particularly for Pharmaceutical Companies and CROs, which are emerging as the fastest-growing entities. This growth is driven by increasing investments in research and development, enhancing diagnostic capabilities, and strategic collaborations within the healthcare ecosystem. The rising prevalence of non alcoholic steatohepatitis and the need for efficient biomarkers are accelerating innovations and demand in this space. Hospitals and Clinics (Dominant) vs. Pharmaceutical Companies and CROs (Emerging) In the India non alcoholic-steatohepatitis-biomarkers market, Hospitals and Clinics play a dominant role as key players due to their frontline position in patient care and treatment protocols. These establishments are essential in conducting tests and diagnostics, thus driving significant market demand. On the other hand, Pharmaceutical Companies and CROs are recognized as emerging players in this arena, benefitting from advancements in technology and a growing focus on precision medicine. Their role in developing biomarkers is crucial in improving treatment outcomes and they are increasingly involved in collaborations and partnerships with research institutions to innovate new solutions for managing this condition. ## Competitive Benchmarking The non alcoholic-steatohepatitis-biomarkers market in India is characterized by a dynamic competitive landscape, driven by increasing prevalence of non-alcoholic fatty liver disease (NAFLD) and a growing emphasis on early diagnosis and treatment. Key players such as Gilead Sciences (US), Intercept Pharmaceuticals (US), and Echosens (FR) are strategically positioned to leverage innovation and partnerships to enhance their market presence. Gilead Sciences (US) focuses on developing novel therapeutics and biomarkers, while Intercept Pharmaceuticals (US) emphasizes its pipeline of non-invasive diagnostic tools. Echosens (FR) is known for its advanced imaging technologies, which are crucial for non-invasive liver assessment, thereby shaping the competitive environment through technological advancements and strategic collaborations.The market structure appears moderately fragmented, with several players vying for market share. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. This trend is indicative of a broader strategy to reduce costs and improve accessibility of biomarkers in the Indian market. The collective influence of these key players fosters a competitive atmosphere where innovation and strategic partnerships are paramount for success. In October Gilead Sciences (US) announced a collaboration with a leading Indian diagnostic firm to enhance the availability of its liver disease biomarkers across the region. This partnership is likely to expand Gilead's reach and improve patient access to critical diagnostic tools, thereby reinforcing its market position. Such collaborations may also facilitate knowledge transfer and local expertise, which are essential for navigating the complexities of the Indian healthcare landscape. In September Intercept Pharmaceuticals (US) launched a new biomarker test aimed at early detection of liver fibrosis, specifically tailored for the Indian population. This strategic move not only addresses a significant unmet need but also positions Intercept as a leader in the diagnostic space. The introduction of this test could potentially enhance patient outcomes and drive market growth, reflecting the company's commitment to innovation and localized solutions. In August Echosens (FR) expanded its operations in India by establishing a new regional office to support its growing customer base. This expansion is indicative of Echosens' strategy to strengthen its market presence and provide localized support for its advanced imaging technologies. By enhancing its operational footprint, Echosens is likely to improve customer engagement and service delivery, which are critical in a competitive market. As of November the competitive trends in the non alcoholic-steatohepatitis-biomarkers market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in diagnostics. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and enhancing market reach. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and adapt to evolving market demands. ## Recent News & Developments Recent developments in the India Non-Alcoholic Steatohepatitis Biomarkers Market indicate significant growth and interest from major companies such as Merck and Co, LabCorp, and Gilead Sciences. The market is seeing advancements in Research and Development efforts aimed at enhancing diagnostic capabilities for Non-Alcoholic Steatohepatitis (NASH). In August 2023, Merck and Co. announced strategic collaborations to accelerate biomarker discovery in liver diseases, which is expected to bolster their market position significantly. In addition, LabCorp's introduction of innovative testing solutions for NASH biomarkers has sparked interest among healthcare providers, addressing the rising prevalence of metabolic disorders in India.  The Indian government has emphasized the importance of early detection and management of liver diseases, further driving the market's growth. There have been no notable mergers or acquisitions among the specified companies in recent months. However, the ongoing focus on biomarker research is likely to lead to increased investments and partnerships, which will transform the landscape of the NASH biomarkers market in India. With rising health consciousness, the demand for effective testing solutions continues to surge, reflecting positively on the market dynamics and growth potential of key players. ## Report Scope | MARKET SIZE 2024 | 6.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 7.57(USD Million) | | MARKET SIZE 2035 | 77.54(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 26.19% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Gilead Sciences (US), Intercept Pharmaceuticals (US), Bristol-Myers Squibb (US), Echosens (FR), Celerion (US), Genfit (FR), Pfizer (US), Novartis (CH), Hepion Pharmaceuticals (US) | | Segments Covered | Type, End User | | Key Market Opportunities | Emerging biomarkers for non alcoholic steatohepatitis enhance early diagnosis and personalized treatment strategies. | | Key Market Dynamics | Rising demand for non alcoholic steatohepatitis biomarkers driven by regulatory changes and technological advancements in diagnostics. | | Countries Covered | India | ## Frequently Asked Questions **Q: What is the current valuation of the India non alcoholic-steatohepatitis-biomarkers market?** A: The market was valued at $6.0 Million in 2024. **Q: What is the projected market valuation for 2035?** A: The market is expected to reach $77.54 Million by 2035. **Q: What is the expected CAGR for the market during the forecast period 2025 - 2035?** A: The expected CAGR for the market is 26.19% during the forecast period. **Q: Which companies are the key players in the market?** A: Key players include Gilead Sciences, Intercept Pharmaceuticals, and Bristol-Myers Squibb, among others. **Q: What are the main segments of the India non alcoholic-steatohepatitis-biomarkers market?** A: The main segments include Hepatic Fibrosis Biomarkers, Serum Biomarkers, and Oxidative Stress Biomarkers. **Q: How much revenue did Hepatic Fibrosis Biomarkers generate in 2024?** A: Hepatic Fibrosis Biomarkers generated $1.2 Million in 2024. **Q: What is the projected revenue for Serum Biomarkers by 2035?** A: Serum Biomarkers are projected to generate $20.0 Million by 2035. **Q: Which end-user segment is expected to dominate the market?** A: Pharmaceutical Companies and CROs are expected to dominate with a projected revenue of $30.0 Million by 2035. **Q: What was the revenue generated by Diagnostic Centres in 2024?** A: Diagnostic Centres generated $1.2 Million in 2024. **Q: What is the expected revenue for Others segment by 2035?** A: The Others segment is expected to reach $4.74 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-non-alcoholic-steatohepatitis-biomarkers-market-49719*